The strong ORR data across multiple tumor types, especially the 67% in pancreatic cancer (a notoriously difficult indication), is a material positive catalyst for KURA. However, the data are from a small Phase 1a study (26 evaluable patients) and the platform study is not expected to begin until early 2027. Traders should watch for the investor event today for additional details and potential partnership interest. Given the early-stage nature, volatility is expected; consider taking profits on any significant run-up.
Price Chart
Executive Summary
Kura Oncology presented Phase 1a data at ASCO 2026 showing darlifarnib + adagrasib achieved confirmed objective response rates of 67% in pancreatic cancer, 50% in NSCLC, and 29% in KRAS inhibitor-naïve colorectal cancer, with tumor shrinkage in 77% of evaluable patients. The company announced a new platform study to accelerate darlifarnib combinations across targeted therapies, starting with darlifarnib + daraxonrasib in KRAS-mutant pancreatic cancer expected in early 2027. This is a significant clinical and strategic update for an early-stage biotech with a $796M market cap, but the data are preliminary and the platform study timeline is distant.
Key Facts
- Darlifarnib + adagrasib showed confirmed ORR of 67% in pancreatic cancer, 50% in NSCLC, and 29% in KRAS inhibitor-naïve CRC among 26 response-evaluable patients.
- Tumor shrinkage observed in 77% of patients overall and 94% of KRAS inhibitor-naïve patients.
- Clinical activity also seen in KRAS inhibitor-pretreated patients.
- Preclinical data show darlifarnib inhibits RHEB farnesylation and sustains mTORC1 suppression, addressing adaptive resistance to KRAS inhibition.
- Kura plans a new platform study to evaluate darlifarnib across multiple targeted therapy combinations and disease settings.
- First planned combination: darlifarnib + daraxonrasib in 2L+ KRAS-mutant pancreatic cancer, expected to enter Phase 1a in early 2027.
- This is the third clinical validation of Kura's FTI combination strategy, following prior data in renal cell carcinoma and PIK3CA-mutated head and neck cancer.
- Kura is hosting a virtual investor event on June 3, 2026.
Financial Impact
No financial data provided; early-stage biotech with $796M market cap. Positive clinical data could drive significant stock movement, but no revenue or guidance disclosed.
Risk Factors
- Data are preliminary from a small Phase 1a trial (n=26) and may not replicate in larger studies.
- Platform study timeline is distant (early 2027), with no guarantee of regulatory acceptance or successful enrollment.
- Kura may not secure access to daraxonrasib or other combination partners.
- Competitive landscape for KRAS inhibitors is rapidly evolving with multiple next-generation agents in development.
- Historical calibration shows high-score bullish calls on KURA have had mixed outcomes (T+20 win rate 67% but negative avg alpha).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305888 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access